You have 9 free searches left this month | for more free features.

PSA (biochemical)

Showing 1 - 25 of 3,679

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Urologic Cancer, Biochemical Recurrence of Malignant Tumor of Prostate Trial in Freiburg (Pembrolizumab Injection [Keytruda],

Recruiting
  • Urologic Cancer
  • Biochemical Recurrence of Malignant Neoplasm of Prostate
  • Pembrolizumab Injection [Keytruda]
  • Salvage Radiation Therapy (SRT)
  • Freiburg, Baden-Württemberg, Germany
    Clinic of Urology, Medical Center - University of Freiburg
Nov 7, 2022

Prostate Cancer Trial in Myrtle Beach (ChAdOx1-PCAQ, MVA-PCAQ)

Recruiting
  • Prostate Cancer
  • ChAdOx1-PCAQ
  • MVA-PCAQ
  • Myrtle Beach, South Carolina
    Carolina Urologic Research Center
Jan 30, 2023

Molecular Forms of PSA and Human Kallikrein 2 inCohort of

Active, not recruiting
  • Prostate Cancer
  • blood draw
  • New York, New York
    Memorial Sloan Kettering Cancer Center
Mar 1, 2022

Prostate Cancer Trial in Lexington (ArtemiCoffee)

Not yet recruiting
  • Prostate Cancer
  • Lexington, Kentucky
    University of Kentucky
Jul 25, 2022

Biochemical Relapse Fo Malignant Tumor of Prostate Trial in Taipei (18F-FACBC PET/CT)

Recruiting
  • Biochemical Relapse Fo Malignant Neoplasm of Prostate
  • 18F-FACBC PET/CT
  • Taipei, Taiwan
    National Taiwan University Hospital
Sep 8, 2021

Prostate Adenocarcinoma, PSA Level Greater Than 0.2, PSA Level Greater Than or Equal to Two Trial in Palo Alto (procedure,

No longer available
  • Prostate Adenocarcinoma
  • +4 more
  • Computed Tomography
  • +3 more
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
Jan 6, 2022

Prostate Adenocarcinoma, PSA Progression, Recurrent Prostate Carcinoma Trial in Palo Alto (Gallium Ga 68 DOTA-NeoBOMB1, Gallium

Suspended
  • Prostate Adenocarcinoma
  • +2 more
  • Gallium Ga 68 DOTA-NeoBOMB1
  • Gallium Ga 68 PSMA-R2
  • Palo Alto, California
    Stanford Cancer Institute Palo Alto
May 3, 2022

Biochemical Recurrence of Malignant Tumor of Prostate, Prostate Cancer, BCR Prostate Carcinoma Trial in China (68Ga-PSMA-11,

Not yet recruiting
  • Biochemical Recurrence of Malignant Neoplasm of Prostate
  • +2 more
  • Changsha, China
  • +5 more
Apr 26, 2023

Prostate Cancer, Biochemical Recurrence Trial in Nanjing (Rezvilutamide, Androgen deprivation therapy (ADT), SRT)

Recruiting
  • Prostate Cancer
  • Biochemical Recurrence
  • Nanjing, Jiangsu, China
  • +1 more
Mar 2, 2023

Prostatic Tumors Trial in Kfar-Saba (PectaSol-C Modified Citrus Pectin (MCP))

Completed
  • Prostatic Neoplasms
  • PectaSol-C Modified Citrus Pectin (MCP)
  • Kfar-Saba, Israel
    Genitourinary Oncology Service, Institute of Oncology, Meir Medi
Jan 27, 2020

After Radical Prostatectomy for Prostate Cancer: Comparing Open

Completed
  • Prostate Cancer
    • Ghent, Belgium
      Ghent University Hospital
    Jan 2, 2023

    Prostate Cancer Trial in United States (Niraparib, Leuprolide, Abiraterone Acetate)

    Recruiting
    • Prostate Cancer
    • Ann Arbor, Michigan
    • +3 more
    Oct 18, 2022

    Prostate Cancer, Salvage Radiotherapy, Biochemical Recurrence Trial (triptorelin, goserelin, leuprorelin)

    Not yet recruiting
    • Prostate Cancer
    • +4 more
    • triptorelin, goserelin, leuprorelin
    • (no location specified)
    Mar 10, 2023

    Adenocarcinoma of the Prostate Trial in United States (Muscadine Plus, Placebos)

    Terminated
    • Adenocarcinoma of the Prostate
    • Muscadine Plus
    • Placebos
    • Duarte, California
    • +12 more
    Dec 6, 2022

    Prostate Cancer Trial (Early salvage radiotherapy (eSRT), Delayed Salvage radiotherapy (dSRT))

    Not yet recruiting
    • Prostate Cancer
    • Early salvage radiotherapy (eSRT)
    • Delayed Salvage radiotherapy (dSRT)
    • (no location specified)
    Aug 2, 2022

    Prostate Cancer Trial in Milan (68Ga-PSMA, 68Ga-RM2)

    Completed
    • Prostate Cancer
    • Milan, Italy
      IRCCS Ospedale San Raffaele
    Apr 5, 2023

    Cancer of Prostate Trial in Ann Arbor (ADT ORDER CHECK ATTESTATION (OR), PROVIDER SCRIPT (SC))

    Active, not recruiting
    • Cancer of Prostate
    • ADT ORDER CHECK ATTESTATION (OR)
    • PROVIDER SCRIPT (SC)
    • Ann Arbor, Michigan
      VA Ann Arbor Healthcare System
    Nov 7, 2022

    Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Tumor in the Bone, Metastatic Prostate Carcinoma Trial in Los

    Terminated
    • Biochemically Recurrent Prostate Carcinoma
    • +5 more
    • Computed Tomography
    • +2 more
    • Los Angeles, California
      University of California at Los Angeles / Jonsson Comprehensive
    Oct 19, 2022

    Prostate Cancer Trial run by the National Cancer Institute (NCI) (PROSTVAC-V, PROSTVAC-F, MSB0011359C (M7824))

    Recruiting
    • Prostate Cancer
    • PROSTVAC-V
    • +3 more
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 23, 2023

    Prostate Cancer Trial in Beijing (Darolutamide+ADT)

    Not yet recruiting
    • Prostate Cancer
    • Beijing, China
      Peking University First Hospital
    Sep 1, 2023

    Psoriatic Arthritis, Obesity Trial in Ankara (diet and biopsychosocial exercise intervention)

    Completed
    • Psoriatic Arthritis
    • Obesity
    • diet and biopsychosocial exercise intervention
    • Ankara, Turkey
      Sümeyra Öteleş
    Dec 4, 2022

    Cancer of Prostate Trial in Bethesda, Philadelphia (Observation and Bicalutamide, Metformin and Bicalutamide)

    Completed
    • Cancer of Prostate
    • Observation and Bicalutamide
    • Metformin and Bicalutamide
    • Bethesda, Maryland
    • +1 more
    Mar 2, 2022

    Biochemical Recurrent Prostate Cancer Trial run by the National Cancer Institute (NCI) (Radium-223, 18F Sodium Fluoride)

    Recruiting
    • Biochemical Recurrent Prostate Cancer
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Feb 2, 2023

    Prostate Cancer Trial in Milwaukee (Pacritinib)

    Recruiting
    • Prostate Cancer
    • Milwaukee, Wisconsin
      Froedtert & the Medical College of Wisconsin
    Jul 18, 2022